the routine practice of therapeutic drug monitoring - some of the results of work in the system of chi
Clicks: 273
ID: 130242
2018
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
Star Article
30.0
/100
273 views
30 readers
AI Quality Assessment
Not analyzed
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
We’ve analyzed results of the therapeutic drug monitoring (TDM). TDM is a routine investigation into the compulsory health insurance system and more than 3 000 TDM-tests are performed annually. The most demanded TDM was the monitoring of antiepileptic drugs, cyclosporin, tacrolimus; rarely were monitored digoxin and antibacterial agents. It turned out that more than % of patients with the application of standard doses of antiepileptic drugs do not reach the therapeutic concentrations of these drugs in the blood of patients. In some patients were observed excess of the therapeutic concentration range: for valproate in 15% of cases, for carbamazepine in 7% of cases. Patients treated with cyclosporine in 9%, and tacrolimus in 17% of cases required a dose adjustment. It is found that the application of various drugs containing the same drug substance in the blood concentration may vary considerably.
| Reference Key |
baturin2018the
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | ;V. A. Baturin;M. V. Baturina;A. A. Kotova;A. A. Skripnyuk |
| Journal | Качественная клиническая практика |
| Year | 2018 |
| DOI |
DOI not found
|
| URL | |
| Keywords |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.